ARTICLE | Clinical News

Lipodox doxorubicin regulatory update

February 27, 2012 8:00 AM UTC

FDA said it will allow the temporary importation and distribution of cancer drug Lipodox doxorubicin from Sun to address the shortage in the U.S. of Doxil doxorubicin from Johnson & Johnson. Doxil has been in short supply due to issues at J&J's contract manufacturer, Ben Venue Laboratories Inc. FDA expects the importation of Lipodox to fully meet patient needs and end the shortage in the "coming weeks." ...